fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

European Commission approves EUR Neffy (epinephrine nasal spray) for emergency treatment of severe allergic reactions in adults and children – ARS Pharma

Written by | 7 Sep 2024

ARS Pharmaceuticals, Inc. announced the European Commission’s approval of EURneffy for emergency treatment of severe allergic reactions in adults and children weighing at least 30 kilograms. This approval… read more.

Nucala (mepolizumab) approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps – GSK

Written by | 6 Sep 2024

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), for the treatment of chronic… read more.

FDA clears Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for use by people with type 2 diabetes – Insulet Corporation

Written by | 5 Sep 2024

Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod brand of products, announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5)… read more.

European Commission approves Balversa (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma – Janssen Cilag (J&J)

Written by | 4 Sep 2024

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has approved Balversa (erdafitinib) as a once-daily oral monotherapy for the treatment of adult… read more.

Ordspono (odronextamab) approved in the European Union for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma – Regeneron Pharma

Written by | 3 Sep 2024

Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) has approved Ordspono (odronextamab) to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse… read more.

UCB to accelerate innovation and strategic partnerships, divesting mature product portfolio in China to CBC Group.

Written by | 2 Sep 2024

UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets…. read more.

FDA clearance of the HYDROS Robotic System, the next-generation, AI-powered platform for aquablation therapy – PROCEPT BioRobotics Corporation

Written by | 1 Sep 2024

PROCEPT BioRobotics Corporation announced FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI treatment planning, advanced… read more.

Leqembi (lecanemab) authorized for early alzheimer’s disease in Great Britain – Eisai + Biogen

Written by | 31 Aug 2024

Eisai Co., Ltd. and Biogen Inc. announced that the humanized amyloid-beta (Abeta monoclonal antibody “Leqembi” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the… read more.

FDA approval & authorization for Omicron KP.2-adapted COVID-19 Vaccine – BioNTech SE + Pfizer

Written by | 30 Aug 2024

Pfizer Inc. and BioNTech SE announced that the FDA has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY (COVID-19 Vaccine, mRNA),… read more.

Update on cannabidiol oral solution phase III trial in Japan in treatment-resistant epilepsies – Jazz Pharma

Written by | 29 Aug 2024

Jazz Pharmaceuticals plc announced top-line results from the Phase III open-label, single-arm trial in Japan evaluating the safety and efficacy of cannabidiol oral solution (marketed as Epidiolex/Epidyolex globally)… read more.

Abbott advances heart failure management with aspirin free regimen for patients receiving the HeartMate 3 heart pump

Written by | 27 Aug 2024

Abbott announced that the FDA has approved a change to its label that will help patients who receive a HeartMate 3 left ventricular assist device (LVAD, or heart… read more.

FDA approval for IPX 203 for treatment of Parkinson’s disease to be launched as Crexont (carbidopa and levodopa) extended-release capsules – Amneal Pharma

Written by | 26 Aug 2024

Amneal Pharmaceuticals, Inc., announced that the FDA has approved Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). Crexont is a novel, oral formulation… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.